New experimental drug enters human testing for Tough-to-Treat cancers
NCT ID NCT05949619
Summary
This early-stage trial is testing an experimental drug called BL-M02D1 in adults with advanced non-small cell lung cancer and other solid tumors that have stopped responding to standard treatments. The study first aims to find a safe and effective dose, then checks if the drug can shrink tumors. It's for patients who have run out of other approved options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.